One in seven Australians currently takes antidepressants. This statistic masks two simultaneous failures:
- We’re medicalizing normal suffering. People with situational depression—responding to loneliness, sedentary lifestyles, and environmental stressors—are getting prescriptions after 15-minute GP appointments without any requirement to attempt behavioral interventions first.
- We’re abandoning people with treatment-resistant depression. After lifestyle changes and therapy fail, the standard path is “try different SSRIs indefinitely” or proceed directly to invasive interventions like ECT. There’s a missing middle.
This isn’t an argument against antidepressants. It’s an argument against lazy prescribing and inadequate treatment algorithms.
First-Line Treatment: What Should Happen Before Medication
The evidence is clear—for mild to moderate depression, lifestyle interventions combined with therapy match or exceed medication efficacy, without side effects or dependency risks. These should be mandatory before prescribing:
Core Interventions (with actual evidence):
- Structured exercise – 150 minutes weekly at 120bpm+. Morning exercise elevates mood baseline for the entire day. This isn’t “wellness culture”—meta-analyses show effect sizes comparable to antidepressants.
- Sleep architecture – Consistent sleep/wake times, light exposure within 30 minutes of waking, sleep restriction therapy if needed.
- Social connection and authentic communication – Loneliness is as dangerous as smoking. Weekly meaningful social contact, daily journaling of honest thoughts, speaking truthfully rather than performing.
- Rumination interruption – Evening gratitude practice (three specific positive events), meditation training, behavioral activation when avoidance patterns emerge.
- Evidence-based supplementation – Weekly high-dose vitamin D (especially if deficient), daily omega-3 (EPA/DHA), B12 if needed. These aren’t magic—they’re addressing common deficiencies that impair mood regulation.
- Reduce depressogenic behaviors – Minimize alcohol (it’s a CNS depressant), eliminate or dramatically reduce social media (the evidence on mental health harm is substantial).
- Future-oriented behavior – Maintain activities to anticipate. Depression collapses time horizons; this counteracts that.
Critical point: These aren’t “lifestyle tips”—they’re evidence-based interventions that should be prescribed, monitored, and reassessed just like medication. The problem is our healthcare system doesn’t fund 12-week lifestyle intervention programs the way it funds antidepressant prescriptions.
When First-Line Treatment Fails: The Current Gap
Here’s what happens in practice:
Someone tries therapy and lifestyle changes. After 3-4 months of rigorous adherence, they’re still depressed. Their GP prescribes an SSRI. It doesn’t work. They try another. Then another. Maybe augmentation with an atypical antipsychotic. Years pass. They’re cycling through medications with minimal improvement.
This is treatment-resistant depression (TRD), affecting roughly 30% of people who try antidepressants. The current options are:
- Continue medication roulette indefinitely
- TMS (transcranial magnetic stimulation)
- ECT (electroconvulsive therapy)
- Esketamine (FDA-approved but limited access)
- Experimental: VNS, DBS
What’s missing: An intervention that enhances the brain’s capacity to respond to therapy and behavioral change before resorting to chronic medication or invasive procedures.
The Neuroplasticity Problem
Why do lifestyle interventions and therapy fail for some people despite genuine effort?
One hypothesis: insufficient neuroplasticity. Depression can create rigid neural patterns—rumination loops, threat bias, anhedonia circuits—that resist modification. Therapy provides new information, but the neural substrate can’t encode it. It’s not that the person isn’t trying; it’s that their brain is in a state that resists rewiring.
This is where the treatment gap exists.
Antidepressants modulate neurotransmitter availability but don’t necessarily restore neuroplasticity. For some people they work remarkably well—particularly melancholic depression with biological features. But for treatment-resistant depression, we need interventions that reopen windows of neural malleability.
Psychedelics: The Emerging Middle Option
Current evidence status: Psilocybin and MDMA show significant promise in clinical trials for treatment-resistant depression and PTSD. Esketamine is FDA-approved. But these are NOT yet standard second-line treatments—they’re available primarily through research protocols and compassionate use programs.
Why they might matter: Psychedelics appear to dramatically increase neuroplasticity for hours to weeks post-administration. In that window, therapy and behavioral interventions that previously failed may finally take root. They don’t “cure” depression—they create neurobiological conditions where therapeutic work becomes possible.
What we know:
- Clinical trials show substantial effect sizes for TRD
- Single-administration protocols (with therapy integration) outperform daily medication in early studies
- Effects appear durable—lasting months after a single session
- Work best when combined with intensive psychotherapy
What we don’t know:
- Long-term safety and efficacy
- Optimal protocols and dosing
- Which subtypes of depression respond best
- Comparative effectiveness vs. current TRD treatments
Critical safety considerations:
- Contraindicated for psychotic disorders, certain personality disorders, cardiovascular conditions
- Require medical supervision and screening
- Can precipitate psychiatric crises in vulnerable individuals
- Not appropriate for mild-moderate depression where other interventions haven’t been tried
A Rational Treatment Hierarchy
For mild-moderate depression:
- Lifestyle interventions + therapy (6-12 months, monitored and adjusted)
- If no improvement: Add medication (SSRI + continued therapy)
- Monitor, adjust, consider tapering if stable
For moderate-severe depression:
- Combined treatment from the start (lifestyle + therapy + medication)
- Aggressive monitoring and adjustment
For treatment-resistant depression (failed multiple interventions):
- Assess what’s actually been tried (most “treatment resistance” is inadequate trials)
- Consider emerging options: psychedelic-assisted therapy, esketamine, TMS
- If those fail: ECT, VNS, DBS
The key principle: Match intervention intensity to severity, but don’t skip steps for mild presentations. And create better options for genuine treatment resistance.
What Needs to Change
Clinical practice:
- Require documented lifestyle intervention + therapy trials before prescribing for mild-moderate depression
- Fund lifestyle intervention programs as primary care
- Systematic medication review every 6-12 months
- Access to psychedelic-assisted therapy for documented TRD
Research priorities:
- Complete Phase III trials for psilocybin and MDMA
- Develop protocols for integration with therapy
- Identify biomarkers for treatment matching
- Study tapering protocols for people who stabilize
Policy:
- Restrict antidepressant prescribing to documented cases where behavioral interventions have failed or severity warrants combined treatment
- Create funding for structured lifestyle intervention programs
- Expand compassionate use access for psychedelics in TRD cases
- Require training in psychedelic therapy for psychiatrists
The Honest Assessment
SSRIs help many people. For some, they’re life-saving. But we’ve created a system where medication is the path of least resistance—for GPs, for patients, for insurers—while evidence-based behavioral interventions remain underfunded and inaccessible.
Simultaneously, we’re failing people with genuine treatment-resistant depression by offering them an endless parade of similar medications instead of fundamentally different approaches.
Psychedelics aren’t a panacea. They’re a promising tool for a specific problem—TRD—that deserves rigorous study and careful implementation. They’re not relevant to the overprescription problem. That’s a healthcare systems failure that requires structural solutions.
We need both: better gatekeeping for initial prescribing AND better options when standard treatments fail.
The current system provides neither.